Potential Rheumatoid Arthritis-Associated Interstitial Lung Disease Treatment and Computational Approach for Future Drug Development

Eunji Jeong,Hyunseok Hong,Yeon-Ah Lee,Kyoung-Soo Kim

DOI: https://doi.org/10.3390/ijms25052682

IF: 5.6

2024-02-27

International Journal of Molecular Sciences

Abstract:Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by swelling in at least one joint. Owing to an overactive immune response, extra-articular manifestations are observed in certain cases, with interstitial lung disease (ILD) being the most common. Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is characterized by chronic inflammation of the interstitial space, which causes fibrosis and the scarring of lung tissue. Controlling inflammation and pulmonary fibrosis in RA-ILD is important because they are associated with high morbidity and mortality. Pirfenidone and nintedanib are specific drugs against idiopathic pulmonary fibrosis and showed efficacy against RA-ILD in several clinical trials. Immunosuppressants and disease-modifying antirheumatic drugs (DMARDs) with anti-fibrotic effects have also been used to treat RA-ILD. Immunosuppressants moderate the overexpression of cytokines and immune cells to reduce pulmonary damage and slow the progression of fibrosis. DMARDs with mild anti-fibrotic effects target specific fibrotic pathways to regulate fibrogenic cellular activity, extracellular matrix homeostasis, and oxidative stress levels. Therefore, specific medications are required to effectively treat RA-ILD. In this review, the commonly used RA-ILD treatments are discussed based on their molecular mechanisms and clinical trial results. In addition, a computational approach is proposed to develop specific drugs for RA-ILD.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problem that this paper attempts to solve is about the effective treatment regimens for rheumatoid arthritis - associated interstitial lung disease (RA - ILD), especially how to control inflammation and pulmonary fibrosis through antifibrotic drugs and computational methods to develop new drugs, thereby improving the prognosis of patients. RA - ILD is a chronic inflammatory disease that can lead to fibrosis and scar formation in lung tissue and is associated with high morbidity and mortality. Current treatment strategies mainly rely on drugs for idiopathic pulmonary fibrosis (IPF), such as Pirfenidone and Nintedanib, but the efficacy and safety of these drugs in RA - ILD still need further study. In addition, traditional immunosuppressants and disease - modifying antirheumatic drugs (DMARDs) also show certain efficacy, but have side effects and limitations. Therefore, the paper explores the efficacy of existing treatment means and proposes the possibility of accelerating new drug development through computational methods, in the hope of finding more effective treatment regimens.